Amnis Bought Out by Division of Merck

EMD Millipore, the life sciences arm of pharmaceutical company Merck, has purchased cell imaging instrument manufacturer Amnis Corporation, reports inpharm.com.

Jonathan DiVincenzo, head of life sciences at EMD, has said that the deal improves the company’s flow cytometry range and will create “tremendous value for our customers’ research outcomes.” Amnis’ products are used in flow cytometry applications across various fields including biotech and pharmaceutical cell analysis.

DiVincenzo went on to add that “with this acquisition, EMD Millipore becomes the only provider of this technology.” David Basiji, Amnis chief executive, believes becoming park of Merck will “accelerate product development”for his company. The deal is expected to go through in the final quarter of this year.

Looking for a job in the science industry? Start by clicking here, now

Posted in Industry News, Mobile News, NewsTagged in , , , , , , , , , , , , , , , , , ,

Promising Scientists to Receive Grant

Cancer Research UK is making an investment into clinical research, reports cslrecruitment.com.

A £12 million grant is to be made to ten promising researchers who are expected to become prominent in the field of cancer. It is intended to assist with the researcher’s careers and possible breakthroughs they could make. Two leading university lecturers, four scientists and four junior research scientists will be the recipients of the grant.

Applicants are being taken, with the deadline at the end of July drawing closer. Dr David Scott, director of science funding at Cancer Research UK, believes the grants show his organisation “is serious about supporting new scientists at the start of their careers.”

Looking for a job in the science industry? Start by clicking here, now

Posted in Industry News, Mobile News, NewsTagged in , , , , , , , , , , , , , , , , , , , ,

TryggPharma Re-opens Teeside Pharma Plant

TryggPharma of Norway is set to re-open a former Lundbeck Pharmaceuticals site in Seal Sands, creating 25 new pharmaceutical jobs, reports peterleemail.com.

A £14 million deal has been agreed in which Lundbeck will sell their site, which they closed during the recession. TryggPharma’s vice president of engineering Peter Harper has said the company is “very impressed with the facility [as it has] easy to access from Norway, Europe and our customers around the world”.

The facility is expected to employ 25 people within 12 months and the company has said there is a “commitment to invest and expand into the future of Teeside”. The North East Process Industry Cluster chief executive Stan Higgins has said the re-opening of the site is “great news for Teeside and for the pharmaceutical sector in particular”.

Looking for a job in science? Start by clicking here now

Posted in Industry News, Mobile News, NewsTagged in , , , , , , , , , , , , , , , , , , , , , , ,

Sanofi and Dendreon Battle for UK Market

Sanofi, a leading pharmaceutical company, has launched new cancer drug Jevtana in the UK, reports inpharm.com.

EMA approval was granted after extensive phase III trials which indicated the drug extended the life of men suffering from a type of prostate cancer considerably. It also slowed the time it took the cancer to progress compared to standard chemotherapy drugs.

However, Sanofi will face competition from US firm Dendreon, as they seek to launch their drug Provenge into the European market. Ultimately, Provenge extends the patient’s life further and reduces the risk of death by nearly 25%, though it would cost £25,000 more to treat a single patient than Jevtana, so would struggle to be able to convince NICE that it is worth the extra cost.

Looking for a job in science? Start by looking here, now

Posted in Industry News, Mobile News, NewsTagged in , , , , , , , , , , , , , , , , , , , , , , ,